Faculty Summaries
Igor Astsaturov, MD, PhD
Igor Astsaturov, MD, PhD
Assistant Professor
  • Attending Physician, Medical Oncology
Treatment Choices Defined by Molecular Profile

The main focus of my research is to improve targeted therapy for cancer, and to develop new rational strategies for combination of targeted agents. In the clinic, epidermal growth factor receptor (EGFR)-targeting antibodies or small kinase inhibitor molecules are widely used to treat patients with gastrointestinal (GI), breast, head and neck, and lung cancers. Unfortunately, the clinical efficacy of these agents is limited by intrinsic primary and acquired resistance factors. Our lab has initially focused on development of new treatment strategies utilizing a systematic synthetic lethal screening approach to identify new signaling proteins that can be blocked simultaneously with EGFR, to improve the anti-cancer activity of EGFR-targeting drugs. We have identified a number of potential therapeutically exploitable targets have been identified (Astsaturov I. et al., Science Signaling (2010)), and ongoing work in the lab assessed their mode of action. Besides testing novel signaling mechanisms in the laboratory, we also are using the research data to generate concepts for testing in the clinical trials. One such clinical trial is ongoing (Vandetanib [a vascular endothelial growth factor receptor (VEGFR) inhibitor] in combination with chemotherapy and radiation for patients with operable esophageal cancer), and several more are in the late stages of preparation.

Description of research projects
Selected Publications

Fox Chase Programs

  1. Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA. Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies. Sci Signal. 2010 Sep 21;3(140):ra67. PMID: 20858866. PubMed
  2. Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Astsaturov I, Hoffman JP. Defining Venous Involvement in Borderline Resectable Pancreatic Cancer. Ann Surg Oncol. 2010 Aug 20. PMID: 20725860. PubMed
  3. Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol. 2010 May 7. PMID: 20458210. PubMed
  4. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal. 2009 Aug;21(8):1255-68. Epub 2009 Mar 1. Review. PMID: 19258037. PubMed
  5. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets. 2009 Mar;13(3):339-62. Review. PMID: 19236156. PubMed
All publications